Purpose Antitachycardia pacing (ATP) terminates the majority (but not all) of slow ventricular
tachycardias (S-VT) with a cycle length (CL)> 320 ms. Usually, several ATP therapies are …

Background Anti‐tachycardia pacing (ATP) delivered from an implantable device is a useful
tool to terminate ventricular tachycardia (VT). But its real‐world efficacy for those patients …

Aims Little is known about the optimal number of antitachycardia pacing (ATP) attempts to
programme in the fast ventricular tachycardia (FVT) zone. We sought to analyse the long …

Introduction: Shock therapy in ICD implanted population has been associated with
increased morbitdity and new programming strategies have been evaluated to reduce ICD …

BACKGROUND: Antitachycardia pacing (ATP) fails to terminate 5% to 25% of ventricular
tachycardias (VTs) occurring in implantable cardioverter-defibrillator patients. We …

Current guidelines recommend at least one attempt of defibrillator antitachycardia pacing
(ATP) therapy, showing preference for burst therapy. The objective of this study is to …

Conclusions First, ATP is a highly effective therapy, independent of patients characteristics.
Second, short VT cycle length and long ATP coupling intervals were identified as predictors …

Background Anti‐tachycardia pacing (ATP) delivered from an implantable device is an
important tool to terminate ventricular tachycardia (VT). But its real‐world efficacy for fast VT …

Introduction Ventricular tachycardia (VT) acceleration due to antitachycardia pacing (ATP)
therapy could be often observed in patients with implantable cardioverter defibrillator (ICD) …

The first implantable cardioverter-defibrillator (ICD) device was developed by Drs Michel
Mirowski and Morty Mower, and successfully implanted in a human being at John Hopkins …